The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

Vertex Pharmaceuticals (NASDAQ:VRTX) continues to dominate the cystic fibrosis (CF) treatment market, but the biotechnology company faces crucial tests as it seeks to expand beyond its core franchise.

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.

Vertex Pharmaceuticals (NASDAQ:VRTX) continues to dominate the cystic fibrosis (CF) treatment market, but the biotechnology company faces crucial tests as it seeks to expand beyond its core franchise.

Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, ...